A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmakokinetic Study of Single Ascending Doses of AAB-001 in Japanese Patients With Mild to Moderate Alzheimer's Disease.
Phase of Trial: Phase I
Latest Information Update: 29 Oct 2014
At a glance
- Drugs Bapineuzumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Wyeth
- 10 Jun 2017 Biomarkers information updated
- 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
- 24 Mar 2009 Planned patient number (24) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History